Literature DB >> 2612239

Ceftriaxone versus cefotaxime in the treatment of septicemia in adults.

A Ferencz1, G Prinz, A Szalka, E Ban.   

Abstract

Two potent third-generation cephalosporins with similar antibacterial spectra but different pharmacokinetics were compared in patients suffering from septicemia due to different organismus. Sixty patients with a variety of underlying diseases were included in the study. They received either 2-4 g ceftriaxone (active ingredient of Rocephin) once a day or 2 g cefotaxime every 8 h for 10-15 days. Our data confirm that a single dose of 2 g ceftriaxone should be sufficient to treat septicemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612239     DOI: 10.1159/000238731

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

Authors:  E T Smyth; J G Barr; C A O'Neill; G M Hogg
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

2.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 3.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.